Synthorxis is a biopharmaceutical company. Co.'s platform technology expands the genetic code by adding a DNA base pair and is designed to create optimized biologics, which it refers to as Synthorins. Co.'s main product candidate, THOR-707, is a variant of innate lymphoid (IL)-2 designed to kill tumor cells by increasing CD8+ T and natural killer cells without causing vascular leak syndrome observed with approved recombinant IL-2 (aldesleukin). Co.'s second IL-2 program is focused on autoimmune disorders based on the observation that low doses of IL-2 can dampen immune cell activation through selective proliferation of CD4+ regulatory T cells. Co. is developing an IL-2 autoimmune Synthorin. The THOR average annual return 10 years is shown above.
The Average Annual Return on the THOR average annual return 10 years page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether THOR average annual return 10 years or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the THOR average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Video: Don't Forget Dividends in Average Annual Return!
